Related News
04Mar
Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders
0 CommentsStevenage, UK – 04 March 2021 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
26Aug
Autifony Therapeutics regains rights to clinical stage Kv3 programme
0 CommentsStevenage, UK – 26 August 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
04May
Autifony Therapeutics announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing disorders
0 CommentsStevenage, UK – 04 May 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
30May
Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders
0 CommentsStevenage, UK – 30 May 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat... Read More →
15Apr
Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator
0 Comments• AUT00206 reduces the ketamine-induced BOLD response in a randomized placebo-controlled Phase Ib trial • Results are highly supportive of... Read More →
Tweets
Autifony Therapeutics and Boehringer Ingelheim to collaborate on novel ion channel target with potential in multipl… https://t.co/KMvOWVf9o5
Autifony Therapeutics regains rights to clinical stage Kv3 programme
https://t.co/rBHjjR7aC0
RT @singular_talent:Barbara Domayne-Hayman joined us on Careers in Discovery to talk startups, careers and more.
Barbara's experience… https://t.co/u0VXnvXlGI
Comments are closed.